Eliem Therapeutics Inc

Research Eliem Therapeutics Inc (CLYM) on Bullrun: market cap USD 765.00M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerCLYM
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 765.00M
• Financial periodFY2025
• Net income-USD 59.85M
• Free cash flow-USD 54.54M

Valuation Snapshot

latest market cap is USD 765.00M.

About Eliem Therapeutics Inc

Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia;

Frequently asked questions

What is Eliem Therapeutics Inc's market cap?

Eliem Therapeutics Inc's market capitalization is USD 765.00M.

What does Eliem Therapeutics Inc do?

Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases.